Zacks.com on MSN3d
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.
American Association of Individual Investors4d
Which Is a Better Investment, Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG Stock?
Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Tal Zaks's Israeli startup targets rare genetic diseases
"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...
GoodNewsNetwork4d
New Base Editing Gene Therapy Cures its First Patient: A Sickle-Cell Sufferer Now in the ‘Gym Every Day’
Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.
Chardan Capital downgrades CARGO Therapeutics, Inc. (CRGX) to a Hold
CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...
Cell Therapy Regenerative Medicine Market Expected To Flourish At 15.78% CAGR To 170.0 Billion USD Gilead Sciences
The Cell Therapy Regenerative Medicine market is poised for significant growth, driven by advancements in technology and increasing acceptanc ...
American Association of Individual Investors4d
Which Is a Better Investment, Legend Biotech Corporation or Twist Bioscience Corporation Stock?
Learn more about whether Legend Biotech Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...